9 Meters Biopharma plans to submit NM-136 IND to FDA in 2H23

9 Meters Biopharma announced receipt of a written response from the U.S. Food and Drug Administration on the request for a Type B pre-IND meeting on the planned pre-clinical development of NM-136 for the treatment of obesity. Based on the response, the Company currently plans to submit an IND to the FDA for this indication in the second half of 2023 based on the completion of the preclinical program. An approved IND is a prerequisite for conducting Phase 1 clinical studies of NM-136 in the U.S.